MEIP - MEI Pharma Inc Stock Price, Fair Value and News

$2.50+0.05 (+2.04%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

MEIP Price Action

Last 7 days

-7.4%

Last 30 days

-10.7%

Last 90 days

-16.1%

Trailing 12 Months

-59.3%

MEIP RSI Chart

MEIP Valuation

Market Cap

16.7M

Price/Earnings (Trailing)

-0.36

Price/Sales (Trailing)

0.26

Price/Free Cashflow

-0.38

MEIP Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

MEIP Fundamentals

MEIP Revenue

Revenue (TTM)

65.3M

Rev. Growth (Yr)

-100%

MEIP Earnings

Earnings (TTM)

-46.6M

Earnings Growth (Yr)

-114.2%

Earnings Growth (Qtr)

56.5%

MEIP Profitability

Return on Equity

-187.33%

Return on Assets

-167.94%

Free Cashflow Yield

-260.74%

MEIP Investor Care

Dividend Yield

70%

Dividend/Share (TTM)

1.75

Diluted EPS (TTM)

-6.99

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	66.8M	65.3M	0	0
2023	58.8M	48.8M	105.4M	72.6M
2022	36.7M	40.7M	41.7M	62.6M
2021	52.8M	34.8M	35.9M	35.2M
2020	4.5M	28.9M	34.4M	46.0M
2019	4.3M	4.9M	5.6M	4.5M
2018	7.0M	1.6M	1.8M	3.5M
2017	18.6M	23.2M	17.8M	12.4M
2016	118.0K	4.7M	9.4M	14.0M
2015	71.0K	78.0K	93.0K	109.0K
2014	79.0K	81.0K	75.0K	60.0K
2013	22.0K	37.0K	52.0K	75.0K
2012	61.8K	39.0K	39.0K	39.0K
2011	0	130.0K	107.3K	84.5K
2010	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

About MEI Pharma Inc

MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymphoma, as well as in Phase Ib multi-arm trial to treat B-cell malignancies; and Voruciclib, an oral cyclin-dependent kinase 9 inhibitor, which is in Phase Ib clinical trial for acute myeloid leukemia and B-cell malignancies. It also develops ME-344, a mitochondrial inhibitor targeting the oxidative phosphorylation complex that is in Phase I clinical trial for the treatment of human epidermal growth factor receptor 2 negative breast cancer; and Pracinostat, an oral available histone deacetylase inhibitor, which is in Phase II clinical trial to treat patients with myelodysplastic syndrome. MEI Pharma, Inc. has a license, development, and commercialization agreement with Kyowa Kirin Company; a clinical collaboration with BeiGene, Ltd.; a license, development, manufacturing, and commercialization agreement with Helsinn Healthcare SA; and a license agreement with Presage Biosciences, Inc. The company was formerly known as Marshall Edwards, Inc. and changed its name to MEI Pharma, Inc. in July 2012. MEI Pharma, Inc. was incorporated in 2000 and is headquartered in San Diego, California.

CEO	Mr. David M. Urso B.A., Esq., J.D.
WEBSITE	meipharma.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	102

MEI Pharma Inc Frequently Asked Questions

What is the ticker symbol for MEI Pharma Inc? What does MEIP stand for in stocks?

MEIP is the stock ticker symbol of MEI Pharma Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of MEI Pharma Inc (MEIP)?

As of Fri Dec 20 2024, market cap of MEI Pharma Inc is 16.66 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MEIP stock?

You can check MEIP's fair value in chart for subscribers.

Is MEI Pharma Inc a good stock to buy?

The fair value guage provides a quick view whether MEIP is over valued or under valued. Whether MEI Pharma Inc is cheap or expensive depends on the assumptions which impact MEI Pharma Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MEIP.

What is MEI Pharma Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Dec 20 2024, MEIP's PE ratio (Price to Earnings) is -0.36 and Price to Sales (PS) ratio is 0.26. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MEIP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on MEI Pharma Inc's stock?

In the past 10 years, MEI Pharma Inc has provided -0.289 (multiply by 100 for percentage) rate of return.